People Science
Los Angeles, California, 90034, United States
Location status: Recruiting
NCT Number: NCT07333885
The purpose of this double-blind, randomized, placebo-controlled trial is to. evaluate daily Reducose® (mulberry leaf extract) supplementation taken with the two largest meals for 12 weeks on improving glycemic response and perimenopausal symptoms in women aged 40-60 years. Glycemic response is measured using Dexcom Stelo continuous glucose monitors during standardized test meals, and menopausal symptoms and sleep/quality-of-life outcomes are assessed using validated surveys administered through the Chloe app in a decentralized U.S. study.
Interested in participating?
Request Info40 year–60 year
Female
Interventional
Not applicable
Los Angeles, California, 90034, United States
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Reducose® proprietary mulberry leaf extract, 250mg, 2/day with meals
Placebo matching capsules, Microcrystalline Cellulose
Time frame: Baseline and end-of-study test meals (Days 10, 14, and 98).
Postprandial glycemic response measured as 0-120-minute incremental area under the curve (iAUC) from interstitial glucose readings captured by Dexcom Stelo CGM.
Time frame: Days 10, 14, and 98.
Time from start of test meal to maximum postprandial glucose level measured by CGM.
Time frame: Days 10, 14, and 98.
Maximum postprandial glucose level (mg/dL) measured by CGM.
Time frame: Days 14 and 98.
Fasting glucose level (mg/dL) obtained from CGM prior to test meals.
Time frame: Baseline (Days 7-14), Week 1 (Days 14-21), Week 11 (Days 85-92), Week 12 (Days 92-98).
CGM-derived glycemic variability metric calculated over predefined baseline and follow-up windows.
Time frame: Baseline (Days 7-14), Week 1 (Days 14-21), Week 11 (Days 85-92), Week 12 (Days 92-98).
CGM-derived nighttime glucose variability from 23:00-06:00.
Time frame: Screening/Day 0, Days 14, 42, 70, 98.
Change in Greene Climacteric Scale (0-60) assessing vasomotor, somatic, psychological symptoms. The minimum possible score is 0 and the maximum possible score is 63 with a score of 21 indicating a woman is experiencing menopause-related symptom patterns. Direction of Improvement: Lower score indicates improvement.
Time frame: Baseline (Day 5) and end of study (Day 98).
Participant-reported sleep disturbance via validated PROMIS Sleep Disturbance-SF6a. For scoring, the raw score range of 8 (lowest possible) to 40 (highest possible). A score of 50 is average for sleep disturbance. Direction of Improvement: Higher score indicates improvement.
Time frame: Baseline (Day 5) and end of study (Day 98).
App-based questionnaires assessing perceived quality of life changes. Direction of Improvement: Higher score indicates improvement.
Time frame: End of study (Day 98)
Questionnaire for experience while taking product and use of Chloe App. Higher score indicates higher satisfaction with product and use of Chloe App,.
Phynova Group Ltd
Industry
The Impact of Reducose® on Symptoms of Perimenopause and Glycemic Response: a Randomized Controlled Trial
Acronym: CALM-R
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07230951
Adult, Appetite
Toronto, Ontario, Canada
View Trial DetailsNCT07243743
Glycemic Response
Toronto, Ontario, Canada
View Trial DetailsNCT07175740
Behavior, Diabetes Mellitus
Québec, Quebec, Canada
View Trial DetailsNCT06797349
Glycemic Response
Toronto, Ontario, Canada
View Trial Details